00:27 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Biothera begins Phase Ib/II trial of Imprime PGG plus Keytruda in NSCLC

Biothera Pharmaceuticals Inc. (Eagan, Minn.) began an open-label, U.S. Phase Ib/II trial to evaluate IV Imprime PGG plus IV Keytruda pembrolizumab in up to 36 patients with non-small cell lung cancer (NSCLC) whose cancer worsened...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
14:05 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; infectious disease

INDICATION: Lupus; sepsis; influenza virus Patient sample, cell culture and mouse studies suggest agonizing CR3 could help treat lupus, sepsis and influenza. Lupus patients harboring loss-of-function SNPs on CR3 had higher serum levels of type...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
02:22 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

Imprime PGG: Ph II started

Biothera began an open-label, U.S. Phase II trial to evaluate IV Imprime PGG plus IV Keytruda pembrolizumab in up to 71 patients with advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy...
20:51 , Feb 9, 2017 |  BC Innovations  |  Translation in Brief

Autoimmunity’s sex bias

It’s well known that autoimmune diseases commonly affect more women than men, but the reason for the bias has been unclear. Now, a University of Michigan team thinks it’s cracked the mystery by pinpointing a...
17:31 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal Monkey studies suggest inhibiting MAC-1 could help treat chronic kidney disease (CKD) associated with acute kidney injury (AKI). In a monkey model of AKI-induced CKD, a mAb inhibiting the CR3 portion of MAC-1...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models Microglia-like cells derived from hPSCs could be used to model cellular pathologies in neurological diseases. The microglia-like cells were generated by plating hPSCs in a serum-free medium containing IL-34 and macrophage colony-stimulating...
07:00 , Oct 13, 2016 |  BC Innovations  |  Translation in Brief

Dodging CARs

Scientists at NIH's National Cancer Institute have discovered a new way in which acute lymphoblastic leukemia (ALL) cells become resistant to CAR T cell therapy: by changing into myeloid cells. The results highlight the remarkable...
08:00 , Jan 11, 2016 |  BioCentury  |  Strategy

Growing up Galapagos

With a new partner for filgotinib, Galapagos N.V. is poised to enter Phase III testing for the first time, after a five-year period of Phase II disappointments and scuttled deals. The new deal with Gilead...